Dr. Qunfeng Luo | Organic Chemistry | Best Researcher Award

Published on by Chemistry Awards

Dr. Qunfeng Luo | Organic Chemistry | Best Researcher Award

Dr. Qunfeng Luo , Organic Chemistry ,  Nanchang University, China

Dr. Qunfeng Luo is a dedicated Lecturer at the School of Basic Medical Sciences, Nanchang University, China. With a robust background in organic synthesis and protein chemistry, his research explores innovative approaches in peptide/protein modification and bioorthogonal chemistry. Dr. Luo has made notable contributions to the development of multifunctional bioconjugation reagents and mitochondrion-targeting molecules, with publications featured in top-tier journals like Nature Communications and Organic Letters. He earned his Ph.D. from Nanjing University and has held research positions at prestigious institutions, including Northwestern Polytechnical University. Dr. Luo also brings industry experience from Pharmaron (Ningbo) New Pharmaceutical Technology Co., Ltd. His work bridges chemical biology and therapeutic discovery, particularly focusing on functional biomolecule engineering and natural active ingredient target identification. A proactive researcher with an ORCID profile, he continues to advance translational biomedical science through interdisciplinary innovations.

Professional Profile : 

Orcid

Scopus

Summary of Suitability for Award:

Dr. Luo has demonstrated a solid and progressive academic background, holding a Ph.D. from Nanjing University and postdoctoral experience in both academia and industry. His education from top Chinese institutions equips him with a multidisciplinary foundation in biomedical and pharmaceutical sciences.His research has been published in top-tier journals such as Nature Communications, Organic Letters, and RSC Advances. Notably, his 2019 Nature Communications paper was highlighted in Synfacts, indicating significant recognition in the global scientific community. Dr. Luo’s work spans organic synthesis, peptide/protein modification, mitochondrion-targeting agents, and bioorthogonal chemistry. Dr. Luo has maintained a consistent output of quality research with a clear upward trajectory in the complexity and impact of his work. His continued research activity, mentorship, and involvement in academia strengthen his candidacy. Dr. Qunfeng Luo is a highly suitable candidate for the “Best Researcher Award”. His impactful publications, innovative methodologies in chemical biology, and contributions to targeted therapeutics and diagnostics reflect the qualities sought in a top-tier researcher. His unique blend of academic excellence, industrial insight, and interdisciplinary work makes him not only a prolific scientist but also a future leader in biomedical research. Recognizing Dr. Luo with this award would be both timely and well-deserved.

🎓Education:

Dr. Qunfeng Luo’s academic journey reflects a strong foundation in medical and pharmaceutical sciences. He began his higher education at Harbin Medical University (2005.9–2010.6), where he gained essential knowledge in medical sciences. Building upon this, he pursued a master’s degree at China Pharmaceutical University (2011.9–2014.6), developing a solid base in drug design and bioactive compound synthesis. Driven by a keen interest in chemical biology and therapeutic research, he advanced to Nanjing University (2014.9–2018.12) for his doctoral studies. There, he specialized in organic synthesis and protein/peptide bioconjugation techniques, which laid the groundwork for his current research in bio orthogonal chemistry and target identification. This comprehensive academic training, combining medical, pharmaceutical, and chemical expertise, enables Dr. Luo to contribute significantly to multidisciplinary biomedical research.

🏢Work Experience:

Dr. Qunfeng Luo has held diverse academic and industry positions, enriching his expertise in biomedical sciences. He began his professional journey at Pharmaron (Ningbo) New Pharmaceutical Technology Co., Ltd. (2019.3–2019.9), gaining valuable experience in pharmaceutical R&D. He then transitioned to academia as a research fellow at Northwestern Polytechnical University (2019.9–2020.10), focusing on bioorganic chemistry and molecular modification. Since October 2020, he has served as a Lecturer at the School of Basic Medical Sciences, Nanchang University, where he leads research in peptide modification, mitochondrion-targeting molecules, and functional bioconjugation reagents. Dr. Luo’s balanced experience across academia and industry fosters a translational approach to his research, bridging synthetic chemistry and medical application. His current academic role involves not only high-impact research but also mentoring students and contributing to the university’s biomedical education initiatives.

🏅Awards: 

While specific honors were not detailed, Dr. Qunfeng Luo’s research achievements speak volumes of his recognition in the scientific community. His 2019 Nature Communications publication was highlighted in Synfacts, indicating significant impact in the field of synthetic and chemical biology. Publishing in top-tier journals like Organic Letters and RSC Advances also reflects the high regard in which his work is held. As a young scholar with an innovative portfolio in bioorthogonal chemistry, peptide/protein modification, and mitochondrion-targeting agents, Dr. Luo is well-positioned for future awards and funding opportunities. His diverse background, including experience in pharmaceutical R&D and academia, contributes to his growing influence in biomedical research. As he continues to contribute to high-impact projects and interdisciplinary science, further accolades are expected.

🔬Research Focus:

Dr. Qunfeng Luo’s research lies at the intersection of organic chemistry and biomedical sciences. His primary interests include organic synthesis, peptide and protein modification, and bioorthogonal chemistry—innovative fields that enable precise molecular labeling and therapeutic design. A major focus of his work is developing heterobifunctional cross-linkers that facilitate selective bioconjugation, peptide stapling, and mitochondrial targeting. He also explores target identification of natural active ingredients, contributing to drug discovery and understanding bioactivity mechanisms. His recent publications reveal an emphasis on multifunctional bioconjugation reagents with broad applications in diagnostics and targeted therapies. The integration of small molecule design with functional biomolecules positions his research within both fundamental and translational biomedical innovation. Through interdisciplinary collaborations and advanced chemical techniques, Dr. Luo’s work contributes to the development of precision tools for chemical biology and therapeutic interventions.

Publication Top Notes:

1. Heterobifunctional Cross-Linker with Dinitroimidazole and Azide Modules for Protein and Oligonucleotide Functionalization

2. Heterobifunctional Cross-Linker with Dinitroimidazole and N-Hydroxysuccinimide Ester Motifs for Protein Functionalization and Cysteine–Lysine Peptide Stapling

3. Combination Therapies against COVID-19

4. Dichloroacetophenone Derivatives: A Class of Bioconjugation Reagents for Disulfide Bridging

5. Dinitroimidazoles as Bifunctional Bioconjugation Reagents for Protein Functionalization and Peptide Macrocyclization

6. Recent Advances in Enone and NO-Releasing Derivatives of Oleanolic Acid with Anti-cancer Activity

 

 

Dr. Hongjian Qin | Organic Chemistry | Best Researcher Award

Published on by Chemistry Awards

Dr. Hongjian Qin | Organic Chemistry | Best Researcher Award

Dr. Hongjian Qin , Shanghai Institute of Materia Medica, CAS , China

Dr. Hongjian Qin is an accomplished researcher in sustainable and green chemistry, with expertise in drug process development and medicinal administration. He earned his Ph.D. in Organic Chemistry from the Chinese Academy of Sciences, being recognized as an Excellent Graduate in 2024. Dr. Hongjian Qin’s contributions to the field span over three years, emphasizing environmentally friendly pharmaceutical synthesis and active pharmaceutical ingredient (API) development. Currently serving as Research Director at Topharman Company Limited, he continues to advance innovative solutions in drug development. His work includes mentoring students, enhancing resource recovery, and participating in COVID-19 research. With numerous impactful publications, Dr. Hongjian Qin is a dedicated professional committed to promoting sustainability and advancing solutions for global environmental challenges.

Professional Profile:

Scopus 

Summary of Suitability for Award:

Dr. Hongjian Qin is an exemplary candidate for the “Best Researcher Awards,” with a distinguished career in sustainable and green chemistry. His pioneering research in eco-friendly pharmaceutical synthesis has significantly contributed to reducing industrial waste and enhancing process efficiency, aligning with global sustainability objectives. Dr. Hongjian Qin’s innovative work on ligand-free catalysis, large-scale API production, and impurity profiling reflects his expertise in developing practical solutions for complex challenges in organic chemistry and medicinal chemistry. Dr. Hongjian Qin’s research excellence, innovative contributions, and global impact make him a highly deserving candidate for the “Best Researcher Awards.” His work not only addresses critical scientific challenges but also fosters sustainable practices in drug development, making a lasting impact on both academia and industry.

🎓Education:

Dr. Hongjian Qin holds a Ph.D. in Organic Chemistry from the Chinese Academy of Sciences , specializing in process development of drug substances and medicinal administration. His doctoral work was conducted at the Key Laboratory of Plant Resources and Chemistry in Arid Regions, showcasing expertise in sustainable pharmaceutical synthesis. He completed a Master of Engineering in Organic Chemistry from Guangxi University, focusing on the process development of drug substances. Dr. Qin’s academic journey began with a Bachelor of Science in Organic Chemistry from Guangxi University . His educational foundation combines rigorous theoretical knowledge with practical applications, preparing him to address complex challenges in green and sustainable chemistry.

🏢Work Experience:

Dr. Hongjian Qin’s professional journey spans over a decade, focusing on pharmaceutical synthesis and sustainable chemistry. As Research Director at Topharman Company Limited (2024–present), he spearheads innovations in active pharmaceutical ingredients (APIs) and emphasizes good manufacturing practices (GMP). Previously, as a Research Assistant at the Shanghai Institute of Materia Medica (2021–2024), he supported COVID-19 research projects, trained students, and enhanced pharmaceutical waste recovery techniques. At the Xinjiang Engineering Research Centre for Key Technologies and Processes of Ethnomedicine (2015–2021), Dr. Hongjian Qin led projects on sustainable API production and industrial resource recovery. His experiences reflect a blend of academic research and industrial application, driving advancements in pharmaceutical science.

🏅Awards: 

Dr. Hongjian Qin has received numerous accolades for his contributions to sustainable chemistry. He was honored as an Excellent Graduate in 2024 by the University of Chinese Academy of Sciences for his outstanding academic achievements during his Ph.D. studies. His work on sustainable pharmaceutical synthesis earned him recognition at various national and international conferences. Dr. Hongjian Qin has been instrumental in developing innovative processes for drug substances, garnering appreciation from industrial partners. Additionally, his mentorship roles and administrative contributions at research institutions have been commended, underscoring his commitment to advancing science and education.

🔬Research Focus:

Dr. Hongjian Qin’s research focuses on sustainable and green chemistry, particularly in the process development of drug substances. He has worked extensively on optimizing synthesis methods for pharmaceutical intermediates, reducing waste, and improving efficiency in drug manufacturing. His innovative approaches emphasize the use of eco-friendly reagents and catalysts, aligning with global sustainability goals. His recent work includes developing ligand-free copper-catalyzed cyclization methods, novel iron-catalyzed cross-coupling reactions, and efficient large-scale processes for active pharmaceutical ingredients (APIs). Dr. Hongjian Qin is dedicated to advancing environmentally responsible techniques in pharmaceutical synthesis, ensuring both industrial viability and ecological preservation.

Publication Top Notes:

1. Direct Esterification of Amides by the Dimethylsulfate-Mediated Activation of Amide C–N Bonds

Authors: Qin, H.; Han, Z.; Bonku, E.M.; Shen, J.; Aisa, H.A.

Year: 2024

Citations: 0

2. An Alternative Approach to Synthesize Sildenafil via Improved Copper-Catalyzed Cyclization

Authors: Odilov, A.; Gong, X.; Qin, H.; Yang, F.; Shen, J.

Year: 2024

Citations: 0

3. Impurity Study of Tecovirimat (Open Access)

Authors: Bonku, E.M.; Qin, H.; Odilov, A.; Wang, X.; Shen, J.

Year: 2024

Citations: 1

4. Improved and Ligand-Free Copper-Catalyzed Cyclization for an Efficient Synthesis of Benzimidazoles from o-Bromoarylamine and Nitriles (Open Access)

Authors: Bonku, E.M.; Qin, H.; Odilov, A.; Aisa, H.A.; Shen, J.

Year: 2024

Citations: 2

5. Direct Reductive N-Alkylation of Amines with Carboxylic Esters

Authors: Zhang, Y.; Bonku, E.M.; Yang, X.; Shen, J.; Qin, H.

Year: 2024 (In Press)

Citations: 0

6. Iron-Catalyzed Cross-Coupling Reactions of Alkyl Grignard Reagents with Alkenyl Carbonate

Authors: Qin, H.; Yang, X.; Mintah Bonku, E.; Shen, J.; Akber Aisa, H.

Year: 2024 (In Press)

Citations: 0

7. A Review of the Synthetic Strategies Toward the Antiviral Drug Tecovirimat (Review Article)

Authors: Bonku, E.M.; Qin, H.; Odilov, A.; Zhu, F.; Shen, J.

Year: 2024 (In Press)

Citations: 0

8. An Improved Iodine-Catalyzed Aromatization Reaction and Its Application in the Synthesis of a Key Intermediate of Cannabidiol

Authors: Abduahadi, S.; Bonku, E.M.; Qin, H.; Aisa, H.A.; Shen, J.

Year: 2024 (In Press)

Citations: 0

9. Optimized Synthesis of the Key Intermediate of Telmisartan via the Cyclization of 2-Bromoarylamine with n-Butyronitrile

Authors: Qin, H.; Mintah Bonku, E.; Odilov, A.; Zhu, F.; Aisa, H.A.

Year: 2023

Citations: 1

10. Efficient Large-Scale Process for Tecovirimat via Reactive Distillation for the Preparation of Cycloheptatriene

Authors: Bonku, E.M.; Qin, H.; Odilov, A.; Guma, S.D.; Shen, J.

Year: 2023

Citations: 4